An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
06 06 2020
06 06 2020
Historique:
received:
20
04
2020
revised:
03
05
2020
accepted:
04
05
2020
pubmed:
16
5
2020
medline:
11
6
2020
entrez:
16
5
2020
Statut:
ppublish
Résumé
The Bergamo province, which is extensively affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic, is a natural observatory of virus manifestations in the general population. In the past month we recorded an outbreak of Kawasaki disease; we aimed to evaluate incidence and features of patients with Kawasaki-like disease diagnosed during the SARS-CoV-2 epidemic. All patients diagnosed with a Kawasaki-like disease at our centre in the past 5 years were divided according to symptomatic presentation before (group 1) or after (group 2) the beginning of the SARS-CoV-2 epidemic. Kawasaki- like presentations were managed as Kawasaki disease according to the American Heart Association indications. Kawasaki disease shock syndrome (KDSS) was defined by presence of circulatory dysfunction, and macrophage activation syndrome (MAS) by the Paediatric Rheumatology International Trials Organisation criteria. Current or previous infection was sought by reverse-transcriptase quantitative PCR in nasopharyngeal and oropharyngeal swabs, and by serological qualitative test detecting SARS-CoV-2 IgM and IgG, respectively. Group 1 comprised 19 patients (seven boys, 12 girls; aged 3·0 years [SD 2·5]) diagnosed between Jan 1, 2015, and Feb 17, 2020. Group 2 included ten patients (seven boys, three girls; aged 7·5 years [SD 3·5]) diagnosed between Feb 18 and April 20, 2020; eight of ten were positive for IgG or IgM, or both. The two groups differed in disease incidence (group 1 vs group 2, 0·3 vs ten per month), mean age (3·0 vs 7·5 years), cardiac involvement (two of 19 vs six of ten), KDSS (zero of 19 vs five of ten), MAS (zero of 19 vs five of ten), and need for adjunctive steroid treatment (three of 19 vs eight of ten; all p<0·01). In the past month we found a 30-fold increased incidence of Kawasaki-like disease. Children diagnosed after the SARS-CoV-2 epidemic began showed evidence of immune response to the virus, were older, had a higher rate of cardiac involvement, and features of MAS. The SARS-CoV-2 epidemic was associated with high incidence of a severe form of Kawasaki disease. A similar outbreak of Kawasaki-like disease is expected in countries involved in the SARS-CoV-2 epidemic. None.
Sections du résumé
BACKGROUND
The Bergamo province, which is extensively affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic, is a natural observatory of virus manifestations in the general population. In the past month we recorded an outbreak of Kawasaki disease; we aimed to evaluate incidence and features of patients with Kawasaki-like disease diagnosed during the SARS-CoV-2 epidemic.
METHODS
All patients diagnosed with a Kawasaki-like disease at our centre in the past 5 years were divided according to symptomatic presentation before (group 1) or after (group 2) the beginning of the SARS-CoV-2 epidemic. Kawasaki- like presentations were managed as Kawasaki disease according to the American Heart Association indications. Kawasaki disease shock syndrome (KDSS) was defined by presence of circulatory dysfunction, and macrophage activation syndrome (MAS) by the Paediatric Rheumatology International Trials Organisation criteria. Current or previous infection was sought by reverse-transcriptase quantitative PCR in nasopharyngeal and oropharyngeal swabs, and by serological qualitative test detecting SARS-CoV-2 IgM and IgG, respectively.
FINDINGS
Group 1 comprised 19 patients (seven boys, 12 girls; aged 3·0 years [SD 2·5]) diagnosed between Jan 1, 2015, and Feb 17, 2020. Group 2 included ten patients (seven boys, three girls; aged 7·5 years [SD 3·5]) diagnosed between Feb 18 and April 20, 2020; eight of ten were positive for IgG or IgM, or both. The two groups differed in disease incidence (group 1 vs group 2, 0·3 vs ten per month), mean age (3·0 vs 7·5 years), cardiac involvement (two of 19 vs six of ten), KDSS (zero of 19 vs five of ten), MAS (zero of 19 vs five of ten), and need for adjunctive steroid treatment (three of 19 vs eight of ten; all p<0·01).
INTERPRETATION
In the past month we found a 30-fold increased incidence of Kawasaki-like disease. Children diagnosed after the SARS-CoV-2 epidemic began showed evidence of immune response to the virus, were older, had a higher rate of cardiac involvement, and features of MAS. The SARS-CoV-2 epidemic was associated with high incidence of a severe form of Kawasaki disease. A similar outbreak of Kawasaki-like disease is expected in countries involved in the SARS-CoV-2 epidemic.
FUNDING
None.
Identifiants
pubmed: 32410760
doi: 10.1016/S0140-6736(20)31103-X
pii: S0140-6736(20)31103-X
pmc: PMC7220177
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1771-1778Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Nat Rev Rheumatol. 2015 Aug;11(8):475-82
pubmed: 25907703
J Infect Dis. 2005 Feb 15;191(4):499-502
pubmed: 15655771
Circulation. 1996 Sep 15;94(6):1379-85
pubmed: 8822996
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063
pubmed: 32293098
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
Pediatr Res. 2020 Sep;88(3):340-341
pubmed: 32244248
J Infect Dis. 2005 Jul 15;192(2):351-2; author reply 353
pubmed: 15962233
Int J Rheum Dis. 2018 Jan;21(1):16-19
pubmed: 29115029
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
Pediatr Infect Dis J. 2010 Jun;29(6):483-8
pubmed: 20104198
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Pediatr Pulmonol. 2020 May;55(5):1085-1086
pubmed: 32243722
Int J Rheum Dis. 2018 Jan;21(1):20-25
pubmed: 29105346
J Epidemiol. 2015;25(3):239-45
pubmed: 25716368
J Med Virol. 2014 Dec;86(12):2146-53
pubmed: 24760654
Ital J Pediatr. 2018 Aug 30;44(1):102
pubmed: 30157897
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Pediatrics. 2009 May;123(5):e783-9
pubmed: 19403470
Pediatrics. 1974 Sep;54(3):271-6
pubmed: 4153258
J Epidemiol. 2012;22(3):216-21
pubmed: 22447211
J Pediatr. 2020 Jul;222:231-235
pubmed: 32444223
Int J Rheum Dis. 2018 Jan;21(1):26-30
pubmed: 29152908
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
J Paediatr Child Health. 2013 Sep;49(9):704-8
pubmed: 23560706
J Pediatr Hematol Oncol. 2017 Aug;39(6):445-451
pubmed: 28562511
J Infect Dis. 2005 Feb 15;191(4):489-91
pubmed: 15655769
Ann Rheum Dis. 2016 Mar;75(3):481-9
pubmed: 26865703
Lancet. 2012 Apr 28;379(9826):1613-20
pubmed: 22405251
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Pediatrics. 2015 Sep;136(3):e609-14
pubmed: 26304824
Semin Arthritis Rheum. 2015 Feb;44(4):405-10
pubmed: 25200945